Skip to main content

Table 3 Antibody-based therapy

From: Novel and emerging therapies for B cell lymphoma

Drug Antigen target Class Patient population N ORR CR Grade 3 AE Ref
Blinatumomab CD-19, CD-3 Bispecific Ab DLBCL, FL, MCL 35 69 %
80% (FL)
71% (MCL)
55% (DLBCL)
40% (FL)
43% (MCL)
36% (DLBCL)
Leukopenia, neurologic event [33]
Blinatumomab CD-19, CD-3 Bispecific Ab DLBCL 25 36% 16% Leukopenia, thrombocytopenia, neurologic event [34]
CD20-Tcb (RG6026) CD-20, CD-3 Bispecific Ab DLBCL,PMBCL, tFL, RT, FL 64 38% 24% None [35]
Mosunetuzumab CD-20, CD-3 Bispecific Ab DLBCL, tFL, FL 98 41% 27% Anemia, neutropenia, hypophosphatemia [36]
Adct-402 (loncastuximab tesirine) CD-19 ADC MCL, FL 30 80% (FL)
46.7% (MCL)
53.3% (FL)
26.7% (MCL)
Increased GGT, neutropenia, anemia [37]
Adct-301 (camidanlumab tesirine) CD-25 ADC B cell NHL
T cell NHL
Immune-related AE: dermatitis exfoliative, thyroiditis [38]
Adct-301 (camidanlumab tesirine) CD-25 ADC HL 60 38% 24% Increased GGT, ALT, AST, and ALP, maculopapular rash, anemia, and thrombocytopenia; immune-related AE: Guillain–Barré syndrome, thyroiditis [39]
MT 3724 CD-20, Shiga-like toxin-I A1 Recombinant fusion protein Ab DLBCL 24 12.5% 4% None [40]
Hu5F9-G4 CD-47 Ab DLBCL, FL 22 50% 36% Pulmonary embolism, ITP, anemia, thrombocytopenia, neutropenia, pyrexia, chills [41]
DCDS0780A CD-79b ADC DLBCL, FL, MCL, MZL 48 40% 14% Neutropenia, thrombocytopenia, hypercalcemia [42]
177 Lu-lilotomab satetraxetan CD-37 Antibody-radionuclide conjugate FL, MCL, MZL, SLL 74 61% 26% Neutropenia, thrombocytopenia, infections [43]
  1. Abbreviations: N number of patients, ORR overall response rate, CR complete response rate, AE adverse events, DLBCL diffuse large B cell lymphoma, CLL chronic leukemic leukemia, tFL transformed follicular lymphoma, FL follicular lymphoma, WM Waldenström’s macroglobulinemia, MZL marginal zone lymphoma, RT Richter’s transformation, MCL mantle cell lymphoma, PMBL primary mediastinal B cell lymphoma, ADC antibody-drug conjugate, GGT gamma-glutamyl transferase, ITP immune thrombocytopenic purpura, AE adverse event, ALT alanine aminotransferase, ALP alkaline phosphatase, Ab antibody